Neurogen Corp.

SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) is saddened to announce the passing of its former President, Srdjan (Serge) Stankovic M.D., M.S.P.H. Serge passed away peacefully on December 29, 2023, following a prolonged illness. “Serge” as he was known to friends and colleagues, joined Acadia in 2015 and led Acadia’s Research and Development organization for more than seven years. He played an instrumental role in Acadia becoming a commercial stage company, providing his significant drug development expertise to the approval and launch of NUPLAZID® (pimavanserin) for the treatment of Parkinson’s disease psychosis and to the approval of Acadia’s second drug to the market, DAYBUE™ (trofinetide) for the treatment of Rett syndrome. Serge served on Acadia’s executive management team and led all research and development efforts until he retired from his role as President at the end of 2022. “This is a moment of profound sadness for those of us who knew Serge. His contributions have left an indelible impact on Acadia, patients and caregivers who will continue to benefit from his work and legacy for decades to come,” said Steve Davis, Acadia’s Chief Executive Officer. “Serge was my dear friend and a frequent sounding board and will be remembered for his intellectual curiosity, sense of humor and passion for science. We mourn his loss and extend our deepest condolences to his wife Ana, his daughter Sandra and Serge’s extended family.” Serge was born in Yugoslavia and received his degree in medicine from the University of Belgrade. He completed his residency in psychiatry there and served as an attending psychiatrist and clinical physician. After emigrating to the U.S., he received his Master of Science in Public Health from the University of Alabama at Birmingham, where he joined the Department of Psychiatry as a research fellow and instructor in Clinical Psychopharmacology. Serge transitioned to the private sector as a medical officer at UCB Pharma and quickly rose through the organization to Vice President of U.S. Clinical Development. He went on to hold leadership positions in research and development at Johnson & Johnson, Neurogen Pharmaceuticals, Forest Laboratories, Teva Pharmaceuticals, and Alkermes. About Acadia Pharmaceuticals Acadia is advancing breakthroughs in neuroscience to elevate life. For 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only FDA-approved drug for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Prader-Willi syndrome, Alzheimer’s disease psychosis and multiple other programs targeting neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at and follow us on LinkedIn and Twitter. View source version on businesswire.com: Contacts Media Contact: Acadia Pharmaceuticals Inc. Deb Kazenelson (818) 395-3043 media@acadia-pharm.com Investor Contact: Acadia Pharmaceuticals Inc. Al Kildani (858) 261-2872 ir@acadia-pharm.com Acadia Pharmaceuticals Inc. Jessica Tieszen (858) 261-2950 ir@acadia-pharm.com Source: Acadia Pharmaceuticals Inc. View this news release online at:

Pictured: View of sky and city scape/Courtesy Getty Images, Nikolay Pandev Layoffs may be frequenting headlines these days, but expansion in the life sciences soldiers on. The industry is growing, and in the month of May, several companies announced expansions and job creation. Biotech Job Creations in May For an update on portended expansions and details about the jobs they will create, continue reading. New Haven The current trajectory of the biotech sector in New Haven, Connecticut, promises continued growth and prosperity. The collaboration between academia, industry and local government has created a conducive ecosystem for scientific breakthroughs and job creation. The transformation of the former New Haven Coliseum site exemplifies the mutually beneficial connection between the high-paying jobs generated by the biotech sector and the upscale apartment units that cater to the resulting employment expansion. "Biotech space is beginning to loosen up," said Anne Benowitz, vice president of economic development and workforce initiatives for the Greater New Haven Chamber of Commerce in a report by CT Insider. "Where we are out of space now is industrial space for warehousing and manufacturing.” Public-private collaborations like the one between Yale faculty and ConnCAT aim to boost New Haven as a biotech hub. Biotechs Alexion Pharmaceuticals, CuraGen Corporation, Genaissance Pharmaceuticals and Neurogen Corporation all call New Haven home. Silicon Valley 10x Genomics, a biotech company specializing in equipment, software and other products for cell analysis, recently unveiled a new office building in Pleasanton as part of its ongoing expansion plans, spanning 150,000 square feet. "This new building will enable us to expand and scale the company. We see increased orders and demand for our products,” said Ben Hindson, chief scientific officer and co-founder of 10x Genomics, in a report by Silicon Valley. The location of the new facility is in close proximity to the company's existing headquarters in Pleasanton. Further, revenue for the company was reported at $134.3 million for the first quarter, representing a 17% increase over the corresponding period of 2022. The products developed by 10x Genomics have focused on cell analysis in biology, including oncology, immunology and neuroscience. Rochester, NY The Crowley Center for Regenerative & Biotherapeutics, formerly known as AT Venture Center, is making strides to expand its operations in the Rochester area. The biotech company works to commercialize various technologies, including advancements in cancer treatments. The decision to expand operations in the Rochester area underscores the company's confidence in the local ecosystem and its potential for continued growth and innovation. As the company scales up its operations, it is expected to create new job opportunities and contribute to the region's economic development, said Michael Crowley, the company’s chairman and CEO, according to a report published in the Rochester Business Journal. The company has alliances, including associations with the Wilmot Cancer Center at the University of Rochester Medical Center and the College of Engineering at the Rochester Institute of Technology. These partnerships allow it to leverage the expertise and resources of academic institutions to drive innovation. Lisa Munger is a senior editor at BioSpace. You can reach her at lisa.munger@biospace.com. Follow her on LinkedIn.

PhaseBio Pharmaceuticals, Inc.(Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, with an initial focus on cardiopulmonary disorders, today announced the appointment of Edmund P. Harrigan, M.D. to its board of directors, effective December 13, 2018. MALVERN, Pa. and SAN DIEGO, Calif., (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, with an initial focus on cardiopulmonary disorders, today announced the appointment of Edmund P. Harrigan, M.D. to its board of directors, effective December 13, 2018. Dr. Harrigan brings nearly three decades of experience in the pharmaceutical industry to PhaseBio’s board. During his 18-year tenure with Pfizer, Dr. Harrigan held numerous leadership roles in business development, regulatory affairs and quality assurance, most recently serving as Senior Vice President of Worldwide Safety and Regulatory, where he led global safety and regulatory organizations. From 2010 to 2012, he served as President and Chief Executive Officer of Karuna Pharmaceuticals. Earlier in his career, Dr. Harrigan held leadership roles at Neurogen Corporation and Sepracor (now Sunovion Pharmaceuticals). Dr. Harrigan began his career as a practicing neurologist and was the co-founder of Coastal Neurology Services. “We are thrilled to welcome Ed to our board of directors,” said Jonathan P. Mow, Chief Executive Officer of PhaseBio. “We will benefit greatly from Ed’s significant pharmaceutical experience in global research and development, regulatory affairs and business development as we continue to execute on corporate milestones and advance PB2452 and PB1046 through clinical trials.” Dr. Harrigan also serves on the boards of directors of Bellicum Pharmaceuticals, Karuna Pharmaceuticals, ACADIA Pharmaceuticals and Lyndra Therapeutics. He holds an M.D. from the University of Massachusetts Medical School and a B.A. in chemistry from Saint Anselm College. “PhaseBio is rapidly progressing product candidates through the clinic and building a portfolio of important medicines to address orphan disease areas of high unmet medical need,” said Dr. Harrigan. “I look forward to working with the PhaseBio leadership team during this exciting time of corporate growth.” About PhaseBio PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary disorders. The company’s lead development candidate is PB2452, a novel reversal agent for the antiplatelet therapy ticagrelor. PhaseBio is also leveraging its proprietary elastin-like polypeptide (“ELP”) technology platform to develop therapies with the potential for less-frequent dosing and improved pharmacokinetics. PhaseBio’s second product candidate PB1046, which is based on ELP, is a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension. PhaseBio is located in Malvern, PA and San Diego, CA. For more information, please visit . Investor Contact: John Sharp PhaseBio Pharmaceuticals, Inc. Chief Financial Officer (610) 981-6506 john.sharp@phasebio.com Media Contact: Sarah Hall 6 Degrees (215) 313-5638 shall@6degreespr.com Source: PhaseBio Pharmaceuticals, Inc.